PIONEERING PRECISION PREVENTION TARGETED THERAPEUTICS FOR NEURODEGENERATIVE DISEASES ACI-7104 in VcSYn Phase 2 - Interim results NASDAQ:ACIU | December 2025 NASDAQ: ACIU | ACI-7104 in VacSYn Phase 2 - Interim results, December 2025 © 2025 AC Immune. Not to be used or reproduced without permission Disclaimer This presentation contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ...